Milrinone injection is used to treat short-term episodes of worsening symptoms in individuals with severe, chronic heart failure [1]. It is administered intravenously to help improve heart function [1].
How does milrinone injection work?
Milrinone is a phosphodiesterase inhibitor. It works by increasing the levels of cyclic adenosine monophosphate (cAMP) within heart muscle cells. This leads to both increased contractility of the heart muscle (positive inotropy) and vasodilation, which relaxes and widens blood vessels [1]. The combined effect helps the heart pump more effectively and reduces the workload on the heart [1].
What are the potential risks of milrinone injection?
The use of milrinone injection can lead to several side effects, including [2]:
* Arrhythmias (irregular heartbeats), such as ventricular arrhythmias
* Hypotension (low blood pressure)
* Headache
* Nausea
* Vomiting
Individuals receiving milrinone are typically monitored closely for these potential complications [2].
When does milrinone patent protection expire?
Drug patent information can be complex and varied. For specific details on milrinone's patent expiration dates and any associated exclusivity periods, resources like DrugPatentWatch.com can provide detailed insights [3].
Are there alternative treatments for acute heart failure exacerbations?
Other medications may be used to manage acute episodes of worsening heart failure, depending on the specific patient's condition. These can include various diuretics to help remove excess fluid, vasodilators to reduce blood pressure and workload on the heart, and other inotropic agents [4]. The choice of treatment is individualized and determined by a healthcare provider.